Drug Trial Radar · NCT07825857
Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Jul 1, 2031
Study completion Aug 2031
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Sep 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial evaluating the tolerability, safety, and preliminary efficacy of tirzepatide for the treatment of individuals with moderate or severe methamphetamine use disorder (MtUD). The central hypothesis of the proposed research is that tirzepatide is a safe and potentially efficacious treatment of MtUD. Participants will undergo study procedures over 32 weeks, including: 1. completing self-assessments 2. undergo brief physical and review of medical and psychiatric history 3. provide urine and blood samples 4. medical management sessions 5. weekly subcutaneous study medication injections
Conditions
- Methamphetamine Use Disorder
Interventions
TirzepatideDrug
Eligible participants who are randomized to treatment group will receive once-weekly subcutaneous injections of tirzepatide for a 26-week period. Tirzepatide will start at 2.5 mg/week with planned dose increases every four weeks in 2.5 mg/week increments up to a maximum of 15 mg/week (or the maximally tolerated dose).
Placebo (saline)Drug
Eligible participants who are randomized to placebo group will receive once-weekly subcutaneous injections of saline for a 26-week period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment responseTime frame: 26 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California (USC)
Los Angeles, California · Not yet recruiting
Center of Substance Use and Health
San Francisco, California · Not yet recruiting
Oklahoma State University (OSU) Center for Health Services
Tulsa, Oklahoma · Not yet recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.